Sanctuary Advisors LLC Raises Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Sanctuary Advisors LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 28.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 183,289 shares of the biopharmaceutical company's stock after purchasing an additional 40,951 shares during the quarter. Sanctuary Advisors LLC's holdings in Gilead Sciences were worth $16,531,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GILD. Lantz Financial LLC increased its holdings in shares of Gilead Sciences by 3.5% in the second quarter. Lantz Financial LLC now owns 24,920 shares of the biopharmaceutical company's stock valued at $1,710,000 after purchasing an additional 840 shares during the last quarter. Triad Wealth Partners LLC purchased a new position in shares of Gilead Sciences during the 2nd quarter worth $63,000. Miracle Mile Advisors LLC boosted its position in shares of Gilead Sciences by 3.5% during the 2nd quarter. Miracle Mile Advisors LLC now owns 7,845 shares of the biopharmaceutical company's stock valued at $538,000 after acquiring an additional 266 shares during the last quarter. Outlook Wealth Advisors LLC purchased a new stake in shares of Gilead Sciences in the second quarter valued at about $334,000. Finally, Blue Trust Inc. increased its position in Gilead Sciences by 280.3% during the second quarter. Blue Trust Inc. now owns 4,712 shares of the biopharmaceutical company's stock worth $345,000 after purchasing an additional 3,473 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of recent analyst reports. Royal Bank of Canada restated a "sector perform" rating and set a $84.00 price target on shares of Gilead Sciences in a report on Wednesday. Leerink Partners raised Gilead Sciences from a "market perform" rating to an "outperform" rating and upped their price target for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Mizuho raised their price objective on Gilead Sciences from $90.00 to $100.00 and gave the stock an "outperform" rating in a research report on Thursday, November 21st. Bank of America reaffirmed a "buy" rating and issued a $109.00 target price on shares of Gilead Sciences in a research report on Tuesday. Finally, Citigroup began coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They set a "buy" rating and a $125.00 price target for the company. Twelve research analysts have rated the stock with a hold rating, twelve have issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $96.43.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the business's stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now directly owns 138,919 shares of the company's stock, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 25,590 shares of the firm's stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. This represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 447,234 shares of company stock worth $41,288,086. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Stock Down 0.0 %

NASDAQ:GILD traded down $0.03 during mid-day trading on Friday, hitting $91.58. The stock had a trading volume of 3,125,238 shares, compared to its average volume of 7,049,561. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The stock has a 50-day simple moving average of $89.82 and a two-hundred day simple moving average of $79.26. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $114.13 billion, a PE ratio of 1,026.44, a PEG ratio of 2.38 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the previous year, the company earned $2.29 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.36%. Gilead Sciences's dividend payout ratio is currently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.